NDAORALSUSPENSION
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
READI-CAT 2 SMOOTHIE (barium sulfate) by Bracco is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 2016.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
READI-CAT 2 SMOOTHIE is an oral barium sulfate suspension used as a radiographic contrast agent to enhance visibility during X-ray imaging procedures. It works by attenuating X-rays, allowing clinicians to visualize the gastrointestinal tract with improved diagnostic clarity. Barium sulfate is insoluble and non-absorbed, making it safe for oral administration.
Peak
Product is at peak lifecycle with moderate competitive pressure (30), indicating stable revenue but limited growth opportunities for brand expansion teams.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Career Relevance
Working on READI-CAT 2 SMOOTHIE offers exposure to mature-stage commercial execution, healthcare provider relationship management, and diagnostic imaging market dynamics. This role builds skills in a stable, non-growth category with emphasis on efficiency, market share defense, and healthcare economics rather than innovation.
Worked on READI-CAT 2 SMOOTHIE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.